IMVT (Immunovant) Other Current Liabilities: $5.26 Mil (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

IMVT Immunovant Inc IMVT
29 GF Score
Price $41.82
! 3 Warning Signs
View Full Analysis

What is Immunovant Other Current Liabilities?

Immunovant IMVT -1.83% 29 Other Current Liabilities is $5.26 Mil as of Jun. 2026. GuruFocus rates IMVT with a GF Score™ of 29/100. The stock has 3 warning signs investors should review.

Immunovant's other current liabilities for the quarter that ended in Jun. 2026 was $5.26 Mil.

Immunovant's quarterly other current liabilities increased from Dec. 2025 ($15.30 Mil) to Mar. 2026 ($16.77 Mil) but then declined from Mar. 2026 ($16.77 Mil) to Jun. 2026 ($5.26 Mil).

Immunovant's annual other current liabilities increased from Mar. 2024 ($14.74 Mil) to Mar. 2025 ($15.62 Mil) and increased from Mar. 2025 ($15.62 Mil) to Mar. 2026 ($16.77 Mil).

Immunovant Other Current Liabilities Related Terms

Immunovant Other Current Liabilities Historical Data

* Premium members only.

The historical data trend for Immunovant's Other Current Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Immunovant Other Current Liabilities Chart

Immunovant Annual Data
Trend Dec18 Mar20 Mar21 Mar22 Mar23 Mar24 Mar25 Mar26
Other Current Liabilities
Get a 7-Day Free Trial 4.46 7.53 14.74 15.62 16.77

Immunovant Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Other Current Liabilities Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 5.98 10.48 15.30 16.77 5.26
IMVT
29GF Score
Immunovant Inc IMVT
Other Current Liabilities is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Immunovant Other Current Liabilities Calculation

The liability a company needs to pay in the next 12 months, but not assigned to Accounts Payable or Debt. For instance, Wal-Mart (WMT) has accrued wages, salaries, valuation, bonuses, insurance liabilities, accrued tax etc. These are all included in other current liabilities.

What does a Other Current Liabilities of $5.26 Mil mean?
Immunovant (IMVT) has a Other Current Liabilities of $5.26 Mil as of Jun. 2026. Other current liabilities as record on a company's balance sheet not categorized as standard liabilities. View historical data on Immunovant.
Is Immunovant's Other Current Liabilities too high?
Immunovant's current Other Current Liabilities is $5.26 Mil. Overall, Immunovant has a GF Score™ of 29/100, reflecting its overall financial health beyond just this single metric.
How does Immunovant's Other Current Liabilities compare to PCVX and TGTX?
Immunovant's Other Current Liabilities of $5.26 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Other Current Liabilities for a Biotechnology company?
A good Other Current Liabilities depends on the Biotechnology industry context. However, Other Current Liabilities should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Other Current Liabilities mean?
A high Other Current Liabilities can signal that a stock is expensive relative to its fundamentals. Other current liabilities as record on a company's balance sheet not categorized as standard liabilities. View historical data on Immunovant. Immunovant's current Other Current Liabilities is $5.26 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Immunovant stock overvalued right now?
Immunovant (IMVT) has a current Other Current Liabilities of $5.26 Mil. The current Other Current Liabilities is $5.26 Mil. Immunovant's overall GF Score™ is 29/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Other Current Liabilities calculated?
Other Current Liabilities is calculated from a company's financial statements. For Immunovant (IMVT), the current Other Current Liabilities is $5.26 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Immunovant Business Description

Address 1000 Park Forty Plaza, New York, NC, USA, 27713
Immunovant Inc is a clinical-stage immunology company dedicated to enabling normal lives for people with autoimmune diseases. Its focus is on developing IMVT-1402, a potential inhibitor of the neonatal fragment crystallizable receptor (FcRn), to address autoimmune diseases driven by high levels of pathogenic immunoglobulin G (IgG) antibodies. FcRn is involved in preventing the degradation of IgG antibodies, and inhibition of FcRn has been shown to reduce levels of total IgG and pathogenic IgG antibodies. The Company operates in a single operating segment and has one reportable segment, which includes all activities related to the discovery, development and manufacturing of its product candidates.
29GF Score

Get the complete analysis for IMVT

Other Current Liabilities is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$41.82
Price